Relacorilant, a cortisol modulator, demonstrated improved blood pressure control in the phase 3 GRACE trial for hypercortisolism patients.
Relacorilant, a selective cortisol modulator, met the primary endpoint in the phase 3 GRACE trial for hypercortisolism, showing improvements in blood pressure control among patients. In the trial, patients with Cushing's syndrome and related conditions experienced significant improvements in hypertension, hyperglycemia, and other symptoms. Corcept Therapeutics plans to submit its application for FDA approval in Q3 2024 based on the data.
May 28, 2024
3 Articles